

Volume 1, Issue 8

Novant Pharmacy

855 Bethesda Road
Winston Salem, NC 27103
Phone: 336-718-4687

Inside this Issue:

Loop Diuretic Therapeutic Interchange Review

MASCOT Report

Formulary Class Reviews

P&T Member Spotlight

Medication Use Policy Subcommittee Report

Editorial Staff:

Michael Nnadi, PharmD, MHS
VP Pharmacy Services


Charles Hartis, Pharm.D.
Clinical Pharmacy Manager

Deanna Rattray, PharmD, BCPS
Clinical Pharmacy Manager

Randi Bridges, PharmD
PGYI Resident- PHC

Laura Bruner, PharmD
PGYI Resident- FMC

Dustin Pippin, PharmD
PGYI Resident- FMC



Intravenous Loop Diuretic Therapeutic Interchange Review

Charles Hartis, Pharm.D.

The IV loop diuretic shortage came to a head in October, causing inconsistency in available product at FMC. In order to expedite drug ordering and delivery, Pharmacy sought an emergency therapeutic interchange of bumetanide and furosemide based on available product at the ratio of 1 mg bumetanide = 40 mg furosemide. This was reviewed and approved at that time by cardiology, nephrology, NICS, and Dr Holmes. Though the shortage is beginning to resolve, P&T approves this interchange system-wide until current supplies are adequate.

Medication Safety Subcommittee (MASCOT) Report

Elizabeth Rebo, PharmD

MASCOT (Novant MedicAtion Safety subCOmmiTtee) met on October 11, 2010.

Francie Carney from PHH reported that the adult and pediatric section of the SPR PICC line order set has been separated into two separate order sets. The order sets are in the process of being posted. This change is due to a medication error where adult and heparin orders were mixed up and profiled incorrectly.

The team discussed the issue of high override rates in holding areas. At PHH, a breakdown of the August override data down into areas that hold versus areas that don't hold found that non-holding areas had 1.4% patient overrides and 3.3% medication overrides whereas holding areas had 18.7% patient overrides and 22% medication overrides. An option to designate "holding area" has been added in Journey for ease of identifying errors associated with this area. This will help management identify trends that need to be addressed with this special population. Risk management reported that a team is being assembled to conduct a failure mode effect analysis (FMEA) on this process. One potential fix is the addition of MAC (medication administration check) for **all** patients that are holding. It was also recommended that data should be collected after implementation which could be used to help support best practice for areas that don't currently utilize MAC.

The team also reviewed MAC patient and medication overrides with data through September. Overall there has been a downward trend for most hospitals in medication and patient overrides.

The Novant anticoagulation team met on October 5th. Order sets for heparin were compared. A separate team will be formed to reconcile differences between the facilities for heparin. The vitamin K and warfarin order sets will be presented for review and discussion at the next meeting.

November Events:

Medication Safety Subcommittee: November 8th
Infectious Disease subcommittee: November 10th
Medication Use Policy Subcommittee: November 12th
Novant P&T Committee: November 18th

Formulary Reconciliation—Class Reviews

This committee will reconcile the formularies across the system by comparing all of the existing formulary agents by AHFS classification and retaining a group of drugs that is determined to be the most beneficial for our patients and will meet the needs of all facilities across the system. Class reviews will be performed by teams of clinical pharmacists from all facilities across the system. The order in which the drug classes will be reviewed was determined by a decision matrix that scored each section by safety, ease and cost. Formulary reconciliation will remain a constant item in this newsletter until the process is complete in 2011.

- | | | |
|---------------------------------|-----------------------------|---------------------------------------|
| 1. Anticonvulsants/Micellaneous | 5. Leukotriene Modifiers | 9. Caloric Agents |
| 2. Gallbladder | 6. Keralytic Agents | 10. Antipuritics and Local Anesthetic |
| 3. Opiate Antagonist | 7. Barbiturates | 11. Cathartics and Laxatives |
| 4. Opiate Partial Agonist | 8. Beta Adrenergic Agonists | |

Formulary Class Review Teams:

Medicine Team I: Andrea Fender, Lorie Poole, Deanna Rattray, Christina Roels

Medicine Team II: Lisa Brennan, Gwen Mitchell, Chue Lee, Kristine Vaden

Medicine Team III: Sara Shields, Lauren Gurganus, Dustin Pippin, Michael Evans

Medicine Team IV: Brock Harris/Amy Holmes, Allison Gaddy, Cam Haskett, Randi Bridges

Surgery/Critical Care Team I: Sara Szafran, Susan Smith, Jackie Olin, Patricia Pinder

Surgery/Critical Care Team II: Jeremy Hodges, Susan Wilson, Laura Bruner, Kevin Morris

Infectious Disease Team: Charles Hartis, Susan Smith

Oncology Team: Christina Ciccarello

Pediatrics Team: Amy Holmes, Brock Harris, Shannon Williams


Cardiovascular Team: Laura Frantz, Ryan Kammer

P&T Member Spotlight

John Lang, Manager of Clinical Systems



John helps coordinate the implementation of P&T formulary decisions in the Siemens Pharmacy/MAC and PYXIS systems in the Greater Winston-Salem Market. John graduated from The University of North Carolina at Chapel Hill and has worked for Novant for 10 years in various roles from a Staff Pharmacist and Pharmacy Supervisor at FMC to his current role as Pharmacy Manager of Clinical Systems for the Corporate Pharmacy Department.



Medication Use Policy Subcommittee

Kathryn Montanya, PharmD, MS

The Medication Use Policy Subcommittee (MUPS) of Novant P&T reviewed the following policies and determined that proper front-line review and full nursing and pharmacy approval was obtained, therefore they were recommended for approval by P&T:

GCM Policies - Medication Administration – Medication Administration Restricted by Location – PCA & Continuous IV Infusion Analgesia – Order Sets – Electrolyte Replacement – Clinical Lactation

TR Policies - Pharmacist Order Writing in Invision – Outpatient Prescriptions – Herbal Medications